Stockscreener 앱 받기
15.16
0.52%
-0.08
시간 외 거래:
15.16
전일 마감가:
$15.24
열려 있는:
$14.93
하루 거래량:
263.01K
Relative Volume:
0.47
시가총액:
$913.78M
수익:
$1.23M
순이익/손실:
$-214.90M
주가수익비율:
-3.6776
EPS:
-4.1222
순현금흐름:
$-151.25M
1주 성능:
-6.77%
1개월 성능:
-2.88%
6개월 성능:
-33.07%
1년 성능:
-39.96%
1일 변동 폭
$14.75
$15.29
1주일 범위
$14.75
$17.01
52주 변동 폭
$10.91
$40.26
Spyre Therapeutics Inc Stock (SYRE) Company Profile
명칭
Spyre Therapeutics Inc
전화
(617) 651-5940
주소
221 CRESCENT STREET, WALTHAM
SYRE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
15.16 | 964.00M | 1.23M | -214.90M | -151.25M | -4.1222 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-08 | 개시 | Leerink Partners | Outperform |
| 2025-03-18 | 개시 | Wolfe Research | Outperform |
| 2024-09-04 | 개시 | Wedbush | Outperform |
| 2024-07-16 | 개시 | Evercore ISI | Outperform |
| 2024-05-02 | 개시 | Robert W. Baird | Outperform |
| 2024-03-01 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-12-11 | 개시 | Guggenheim | Buy |
| 2023-12-11 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2019-03-21 | 개시 | JP Morgan | Overweight |
| 2018-09-04 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | 개시 | Evercore ISI | Outperform |
| 2018-03-14 | 재확인 | Needham | Buy |
모두보기
Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스
Real time scanner hits for Spyre Therapeutics Inc. explainedReliable Setup Screener with Low Risk - Newser
Spyre Therapeutics Inc. Consolidation Zone May Signal AccumulationBreakout Momentum Picks With Protection Outlined - beatles.ru
Is now a turning point for Spyre Therapeutics Inc.Bear Market Safe Zone Technical Analysis - Newser
Will a bounce in Spyre Therapeutics Inc. offer an exitChart Confirmation Setup with ROI Signals - Newser
Why Spyre Therapeutics Inc. stock attracts strong analyst attentionWeekly Growth Portfolio Performance Summary - Newser
Applying sector rotation models to Spyre Therapeutics Inc.Smart Trend Analysis With Buy Point Cues - Newser
Can Spyre Therapeutics Inc. expand its profit marginsFree Trading Community Access - thegnnews.com
Can momentum traders help lift Spyre Therapeutics Inc.Free Weekly Chart Analysis With Entry Advice - Newser
Will Spyre Therapeutics Inc. rebound enough to break evenEquity Signal Recap With Long-Term Summary - Newser
What moving averages say about Spyre Therapeutics Inc.Intraday Strategy with Real Time Monitoring - Newser
What’s the recovery path for long term holders of Spyre Therapeutics Inc.Free AI Forecast for Trending Stocks - Newser
Analyzing drawdowns of Spyre Therapeutics Inc. with statistical toolsWeekly Stock Movement Prediction Watchlist - Newser
Is Spyre Therapeutics Inc. forming a bottoming baseEarly Entry Planner for Swing Candidates - Newser
How Spyre Therapeutics Inc. stock performs during market volatilityMulti-Bagger Detection with Trend Tools - Newser
What institutional flow reveals about Spyre Therapeutics Inc.AI Generated Buy/Sell Signal Forecast - Newser
What data driven models say about Spyre Therapeutics Inc.’s futureConsistent Profit Signals with AI Models - Newser
Using AI based signals to follow Spyre Therapeutics Inc.Downside Control Plan With Support Analysis - Newser
Spyre (SYRE) Q2 R&D Up 23% Loss Narrows - Nasdaq
Using flow based indicators on Spyre Therapeutics Inc.Free Daily Top Performing Stock Insights - Newser
Stifel reiterates Buy rating on Spyre stock with $71 price target - Investing.com Canada
Spyre Therapeutics: Q2 Earnings Snapshot - New Haven Register
Combining machine learning predictions for Spyre Therapeutics Inc.Safe Entry Strategy with High Win Rate - Newser
Spyre Therapeutics Reports Q2 2025 Financial Results - TipRanks
Visual trend scoring systems applied to Spyre Therapeutics Inc.AI Volatility Forecast and Risk Monitor - Newser
Spyre Therapeutics: A Biotech Turnaround Story? Evaluating Operational Efficiency and Earnings Resilience in a High-Risk Sector - AInvest
Spyre Therapeutics's 15min chart sees KDJ Golden Cross, Bullish Marubozu pattern confirmed. - AInvest
Market reaction to Spyre Therapeutics Inc.’s recent newsTechnical Reversal Pattern Summary and Tracker - Newser
Spyre Therapeutics Inc. Uptrend in Early Stages Indicators Say YesDaily Smart Money Movement Monitor Activated - beatles.ru
Moving Average Trends for Spyre Therapeutics Inc. Stock: What They IndicateTechnical Long-Term Outlook and Recap Guide - Newser
How does Spyre Therapeutics Inc. compare to its industry peersGet daily expert analysis on top stocks - Jammu Links News
Should I hold or sell Spyre Therapeutics Inc. stock in 2025Achieve breakthrough profits with expert advice - Jammu Links News
Is it the right time to buy Spyre Therapeutics Inc. stockBuild wealth with steady, reliable stocks - Jammu Links News
What is the dividend policy of Spyre Therapeutics Inc. stockExponential return rates - Jammu Links News
Is Spyre Therapeutics Inc. stock overvalued or undervaluedMarket-leading growth rates - Jammu Links News
What catalysts could drive Spyre Therapeutics Inc. stock higher in 2025Get exclusive market insights for better trading - Jammu Links News
What are analysts’ price targets for Spyre Therapeutics Inc. in the next 12 monthsInvest in high-yield stocks with confidence - Jammu Links News
What makes Spyre Therapeutics Inc. stock price move sharplyBuild a diversified portfolio for risk management - Jammu Links News
What are the technical indicators suggesting about Spyre Therapeutics Inc.High-octane financial growth - Jammu Links News
How hedge fund analytics apply to Spyre Therapeutics Inc. stockFree Trade Insight With Community Collaboration - Newser
Spyre Therapeutics Inc (SYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):